Reducing the HBV load in pregnant women can reduce mother-to-child transmission of HBV, and high levels of HBV in pregnant women are a high-risk factor for mother-to-child transmission. The use of lamivudine or tebivudine in mid- and late-pregnancy has been reported in the literature to reduce HBV transmission from mother to child. The literature reports that treatment with lamivudine or telbivudine during mid- and late pregnancy can reduce mother-to-child transmission, but the design of these studies is flawed, including pregnant women with positive HBeAg as an indication for conventional antiviral therapy. Therefore, whether anti-HBV therapy is administered to HBV-infected pregnant women during pregnancy to reduce mother-to-child transmission remains to be confirmed in more rigorously designed, large-sample, multicenter randomized controlled studies. Pregnant women with HBV infection combined with abnormal liver function during pregnancy do not increase the risk of mother-to-child transmission of HBV, and most patients with abnormal liver function after delivery can return to normal. The indications for anti-HBV therapy during pregnancy in pregnant women with HBV infection should be strictly controlled. The basis for caution in anti-HBV therapy for pregnant women includes: 1. Nucleic acid analogs cannot clear HBV, and the HBV load is higher after drug discontinuation, even inducing serious liver function damage in pregnant women; long-term anti-HBV therapy can lead to HBV mutation, drug resistance and other adverse effects. 2.Long-term anti-HBV treatment can increase the economic burden of pregnant women. 3.Anti-HBV treatment is usually started in the middle and late pregnancy, and is not effective for intrauterine HBV infection in the early and middle pregnancy. 4, 85%-95% of HBeAg-positive pregnant women can be protected after regular prevention of newborns even without anti-HBV treatment.